低密度脂蛋白受体：为胰腺肿瘤细胞提供营养的一条开放途径。
LDL Receptor: An open route to feed pancreatic tumor cells.
作者信息
Vasseur Sophie, Guillaumond Fabienne
机构信息
INSERM, U1068, Centre de Recherche en Cancérologie de Marseille, Marseille, France; Institut Paoli-Calmettes, Marseille, France; CNRS, UMR7258, Marseille, France; Université Aix-Marseille, Marseille, France.
出版信息
Mol Cell Oncol. 2015 May 7;3(1):e1033586. doi: 10.1080/23723556.2015.1033586. eCollection 2016 Jan.
Abstract
The role of altered lipid metabolism in pancreatic ductal adenocarcinoma (PDAC) is poorly appreciated. We recently identified the lipid signature of PDAC and revealed low-density lipoprotein receptor (Ldlr) as a metabolic driver of this disease. Here, we comment our findings that disruption of Ldlr leads to intratumoral cholesterol imbalance and improves chemotherapy efficiency.
摘要
脂质代谢改变在胰腺导管腺癌（PDAC）中的作用尚未得到充分认识。我们最近确定了PDAC的脂质特征，并揭示低密度脂蛋白受体（Ldlr）是这种疾病的代谢驱动因素。在此，我们对我们的研究结果进行评论，即Ldlr的破坏会导致肿瘤内胆固醇失衡并提高化疗效率。
相似文献
1
LDL Receptor: An open route to feed pancreatic tumor cells.低密度脂蛋白受体：为胰腺肿瘤细胞提供营养的一条开放途径。
Mol Cell Oncol. 2015 May 7;3(1):e1033586. doi: 10.1080/23723556.2015.1033586. eCollection 2016 Jan.
2
A lipidomics study reveals hepatic lipid signatures associating with deficiency of the LDL receptor in a rat model.脂质组学研究揭示了与 LDL 受体缺乏相关的肝脂质特征在大鼠模型中的存在。
Biol Open. 2016 Jul 15;5(7):979-86. doi: 10.1242/bio.019802.
3
Non-physiological overexpression of the low density lipoprotein receptor (LDLr) gene in the liver induces pathological intracellular lipid and cholesterol storage.肝脏中低密度脂蛋白受体（LDLr）基因的非生理性过表达会诱导细胞内病理性脂质和胆固醇蓄积。
J Gene Med. 2004 Feb;6(2):166-75. doi: 10.1002/jgm.473.
4
Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents.肿瘤内细菌可能通过代谢抗癌药物引发化疗耐药。
Mol Cell Oncol. 2017 Dec 11;5(1):e1405139. doi: 10.1080/23723556.2017.1405139. eCollection 2018.
5
Circular RNA Signature Predicts Gemcitabine Resistance of Pancreatic Ductal Adenocarcinoma.环状RNA特征预测胰腺导管腺癌对吉西他滨的耐药性。
Front Pharmacol. 2018 Jun 5;9:584. doi: 10.3389/fphar.2018.00584. eCollection 2018.
6
USP44 suppresses pancreatic cancer progression and overcomes gemcitabine resistance by deubiquitinating FBP1.USP44通过去泛素化FBP1抑制胰腺癌进展并克服吉西他滨耐药性。
Am J Cancer Res. 2019 Aug 1;9(8):1722-1733. eCollection 2019.
7
The COMMD Family Regulates Plasma LDL Levels and Attenuates Atherosclerosis Through Stabilizing the CCC Complex in Endosomal LDLR Trafficking.COMMD 家族通过稳定内体 LDLR 运输中的 CCC 复合物来调节血浆 LDL 水平并减轻动脉粥样硬化。
Circ Res. 2018 Jun 8;122(12):1648-1660. doi: 10.1161/CIRCRESAHA.117.312004. Epub 2018 Mar 15.
8
Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient ( and ) Yucatan Miniature Pigs.贝匹地酸降低 LDL 胆固醇并减轻 LDL 受体缺陷（和）尤卡坦小型猪的动脉粥样硬化。
Arterioscler Thromb Vasc Biol. 2018 May;38(5):1178-1190. doi: 10.1161/ATVBAHA.117.310676. Epub 2018 Feb 15.
9
MicroRNA-410-3p attenuates gemcitabine resistance in pancreatic ductal adenocarcinoma by inhibiting HMGB1-mediated autophagy.微小RNA-410-3p通过抑制高迁移率族蛋白B1介导的自噬减轻胰腺导管腺癌对吉西他滨的耐药性。
Oncotarget. 2017 Nov 18;8(64):107500-107512. doi: 10.18632/oncotarget.22494. eCollection 2017 Dec 8.
10
Perspectives in the treatment of pancreatic adenocarcinoma.胰腺腺癌的治疗前景
World J Gastroenterol. 2015 Aug 21;21(31):9297-316. doi: 10.3748/wjg.v21.i31.9297.
引用本文的文献
1
Engineering Fusion Proteins for Nanomedicine-Based Cytokine Therapy.用于基于纳米医学的细胞因子治疗的工程融合蛋白
Bioconjug Chem. 2025 Aug 20;36(8):1698-1708. doi: 10.1021/acs.bioconjchem.5c00182. Epub 2025 Jul 11.
2
Cystic Fluid Total Proteins, Low-Density Lipoprotein Cholesterol, Lipid Metabolites, and Lymphocytes: Worrisome Biomarkers for Intraductal Papillary Mucinous Neoplasms.囊液总蛋白、低密度脂蛋白胆固醇、脂质代谢产物和淋巴细胞：导管内乳头状黏液性肿瘤的不良生物标志物
Cancers (Basel). 2025 Feb 14;17(4):643. doi: 10.3390/cancers17040643.
3
Combined PET Radiotracer Approach Reveals Insights into Stromal Cell-Induced Metabolic Changes in Pancreatic Cancer In Vitro and In Vivo.联合PET放射性示踪剂方法揭示了基质细胞诱导的胰腺癌体外和体内代谢变化的见解。
Cancers (Basel). 2024 Oct 4;16(19):3393. doi: 10.3390/cancers16193393.
4
Biocompatible and bioactivable terpolymer-lipid-MnO Nanoparticle-based MRI contrast agent for improving tumor detection and delineation.用于改善肿瘤检测与勾勒的基于生物相容性和可生物活化的三元共聚物-脂质-MnO纳米颗粒的磁共振成像造影剂。
Mater Today Bio. 2024 Jan 17;25:100954. doi: 10.1016/j.mtbio.2024.100954. eCollection 2024 Apr.
5
LRP1 as a promising therapeutic target for gastrointestinal tumors: Inhibiting proliferation, invasion and migration of cancer cells.LRP1作为胃肠道肿瘤有前景的治疗靶点：抑制癌细胞的增殖、侵袭和迁移。
Oncol Lett. 2023 Aug 22;26(4):432. doi: 10.3892/ol.2023.14019. eCollection 2023 Oct.
6
Cholesterol homeostasis and cancer: a new perspective on the low-density lipoprotein receptor.胆固醇稳态与癌症：对低密度脂蛋白受体的新视角
Cell Oncol (Dordr). 2022 Oct;45(5):709-728. doi: 10.1007/s13402-022-00694-5. Epub 2022 Jul 22.
7
The Multifaceted Biology of PCSK9.载脂蛋白 C-III（APOC3）基因的多态性与甘油三酯水平升高和心血管疾病（CVD）风险增加有关。
Endocr Rev. 2022 May 12;43(3):558-582. doi: 10.1210/endrev/bnab035.
8
Involvement of LDL and ox-LDL in Cancer Development and Its Therapeutical Potential.低密度脂蛋白和氧化型低密度脂蛋白在癌症发展中的作用及其治疗潜力。
Front Oncol. 2022 Feb 16;12:803473. doi: 10.3389/fonc.2022.803473. eCollection 2022.
9
Peptides against Low Density Lipoprotein (LDL) Aggregation Inhibit Intracellular Cholesteryl Ester Loading and Proliferation of Pancreatic Tumor Cells.抗低密度脂蛋白（LDL）聚集的肽可抑制胰腺肿瘤细胞内胆固醇酯的负载及增殖。
Cancers (Basel). 2022 Feb 11;14(4):890. doi: 10.3390/cancers14040890.
10
KRAS, A Prime Mediator in Pancreatic Lipid Synthesis through Extra Mitochondrial Glutamine and Citrate Metabolism.KRAS，通过额外的线粒体谷氨酰胺和柠檬酸代谢在胰腺脂质合成中的主要介质。
Int J Mol Sci. 2021 May 11;22(10):5070. doi: 10.3390/ijms22105070.
本文引用的文献
1
Metabolic rewiring of pancreatic ductal adenocarcinoma: New routes to follow within the maze.胰腺导管腺癌的代谢重编程：迷宫中可供追寻的新路径。
Int J Cancer. 2016 Feb 15;138(4):787-96. doi: 10.1002/ijc.29501. Epub 2015 Mar 18.
2
Pancreatic cancer: Disrupted lipid metabolic pathways in PDAC identified.
Nat Rev Gastroenterol Hepatol. 2015 Apr;12(4):188. doi: 10.1038/nrgastro.2015.32. Epub 2015 Feb 24.
3
Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma.胆固醇摄取阻断联合化疗是一种有前景的胰腺癌联合代谢疗法。
Proc Natl Acad Sci U S A. 2015 Feb 24;112(8):2473-8. doi: 10.1073/pnas.1421601112. Epub 2015 Feb 9.
4
Association between cholesterol intake and pancreatic cancer risk: evidence from a meta-analysis.胆固醇摄入量与胰腺癌风险之间的关联：一项荟萃分析的证据。
Sci Rep. 2015 Feb 4;5:8243. doi: 10.1038/srep08243.
5
Famine versus feast: understanding the metabolism of tumors in vivo.饥荒与盛宴：理解体内肿瘤的代谢
Trends Biochem Sci. 2015 Mar;40(3):130-40. doi: 10.1016/j.tibs.2015.01.004. Epub 2015 Jan 29.
6
Pancreatic adenocarcinoma.胰腺腺癌
N Engl J Med. 2014 Sep 11;371(11):1039-49. doi: 10.1056/NEJMra1404198.
7
O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway.O-GlcNAcylation 通过调节 HIF-1 通路来调节癌症代谢和生存应激信号。
Mol Cell. 2014 Jun 5;54(5):820-31. doi: 10.1016/j.molcel.2014.04.026. Epub 2014 May 22.
8
Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids.脂肪生成和脂肪分解：癌细胞获取脂肪酸所利用的途径。
Prog Lipid Res. 2013 Oct;52(4):585-9. doi: 10.1016/j.plipres.2013.08.005. Epub 2013 Aug 31.
9
Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma.缺氧条件下增强的糖酵解支持胰腺腺癌中的肿瘤共生和己糖胺生物合成。
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3919-24. doi: 10.1073/pnas.1219555110. Epub 2013 Feb 13.
10
Phosphofructokinase 1 glycosylation regulates cell growth and metabolism.磷酸果糖激酶 1 糖基化调节细胞生长和代谢。
Science. 2012 Aug 24;337(6097):975-80. doi: 10.1126/science.1222278.
Zotero 插件